Search Result

Results for "

malignant gliomas

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) c-Met/HGFR (1) Carbonic Anhydrase (1) Cytochrome P450 (4) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Endogenous Metabolite (4) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (1) HIV (4) HIV Protease (4) Isotope-Labeled Compounds (1) Liposome (1) P-glycoprotein (4) PI3K (1) PROTAC Linkers (1) Ras (1) Reference Standards (1) SARS-CoV (4) TNF Receptor (1) Toll-like Receptor (TLR) (3)
By Research Areas:	Cancer (11) Cardiovascular Disease (3) Infection (4)

By Targets:

Apoptosis (1)

c-Met/HGFR (1)

Carbonic Anhydrase (1)

Cytochrome P450 (4)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (1)

Endogenous Metabolite (4)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Acetyltransferase (1)

HIV (4)

HIV Protease (4)

Isotope-Labeled Compounds (1)

Liposome (1)

P-glycoprotein (4)

PI3K (1)

PROTAC Linkers (1)

Ras (1)

Reference Standards (1)

SARS-CoV (4)

TNF Receptor (1)

Toll-like Receptor (TLR) (3)

By Research Areas:

Cancer (11)

Cardiovascular Disease (3)

Infection (4)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15735

c-Met inhibitor 1 1 Publications Verification	c-Met/HGFR	Cancer
c-Met inhibitor 1 is an orally active c-Met inhibitor. c-Met inhibitor 1 can inhibit c-Met phosphorylation with an IC₅₀ of 0.010 μM. c-Met inhibitor 1 has antitumor activity and can be used for the research of tumors such as gastric cancer, pancreatic cancer and malignant glioma .

HY-W156324

Biotin-PEGn-NHS ester	PROTAC Linkers Liposome	Others
Biotin-PEGn-NHS ester is a biotin-labeled PROTAC linker, which belongs to the PEG class and can be used to synthesize PROTAC molecules. Biotin-PEGn-NHS ester can interact with free neutral avidin in solution and successfully target malignant glioma cells. Biotin-PEGn-NHS ester can also be grafted onto the amino group of GelMA to prepare biotin-modified functionalized hydrogel, gelatin methacryloyl (Bio-GelMA) .

HY-17367

Atazanavir Maximum Cited Publications 11 Publications Verification BMS-232632	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)	Infection Cardiovascular Disease Cancer
Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-17367A

Atazanavir sulfate Maximum Cited Publications 11 Publications Verification BMS-232632 sulfate	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)	Infection Cardiovascular Disease Cancer
Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-13440

AMG 511 2 Publications Verification	PI3K	Cancer
AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks, with K_is of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 significantly suppresses PI3K signaling that is indicated by p-Akt (Ser473) decrease. AMG 511 exhibits anti-tumor activity in mouse glioblastoma xenograft model .

HY-P99772

Onfekafusp alfa L19TNF	TNF Receptor	Cancer
Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .

HY-173116

DOTA-XYIMSR-01	Carbonic Anhydrase	Cancer
DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy .

HY-123009

KCN1	HIF/HIF Prolyl-Hydroxylase Histone Acetyltransferase	Cancer
KCN1 is a p300/HIF-1α interaction inhibitor. KCN1 inhibits HIF transcriptional activity by binding to the CH1 domain of p300 and preventing the p300/HIF-1α assembly. KCN1 exerts antitumor activities through cell cycle arrest .

HY-17367R

Atazanavir (Standard) BMS-232632 (Standard)	Reference Standards HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite	Infection Cancer
Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-17367S5

Atazanavir-d24 BMS-232632-d₂₄	Isotope-Labeled Compounds P-glycoprotein SARS-CoV Endogenous Metabolite HIV Cytochrome P450 HIV Protease Toll-like Receptor (TLR)	Infection Cardiovascular Disease Cancer
Atazanavir-d₂₄ (BMS-232632-d₂₄) is deuterium labeled Atazanavir. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-106435

Cystemustine	DNA/RNA Synthesis DNA Alkylator/Crosslinker	Cancer
Cystemustine is a DNA inhibitor (a chloroethyl nitrosourea, CENU). Cystemustine can cause DNA cross-linking, thereby inhibiting the proliferation of tumor cells. Cystemustine can also exert cytotoxic effects by interfering with the cell cycle, inducing cell re-differentiation, and altering phospholipid metabolism. Cystemustine exhibits high anti-tumor activity and a relatively short plasma half-life in mice. Cystemustine can be used for the study of various malignant tumors, including melanoma, glioma, renal cancer, head and neck cancer, and colorectal cancer, etc .

HY-102078

ZINC69391 1 Publications Verification	Ras Apoptosis	Cancer
ZINC69391, a specific Rac1 inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels. ZINC69391 induces apoptosis, and shows antiproliferative and antimetastatic effects .

Cat. No.	Product Name	Target	Research Area

HY-P99772

Onfekafusp alfa L19TNF	TNF Receptor	Cancer
Onfekafusp alfa (L19TNF) is a homotrimer that forms from engineered peptides for the L19 antibody in scFv format fused to human TNF. Onfekafusp alfa can be used for malignant glioma research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17367

Atazanavir 10+ Cited Publications BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)
Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-17367A

Atazanavir sulfate 10+ Cited Publications BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite Toll-like Receptor (TLR)
Atazanavir (BMS-232632) sulfate is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir sulfate inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

HY-17367R

Atazanavir (Standard) BMS-232632 (Standard)	Structural Classification Alkaloids Source classification Pyridine Alkaloids Endogenous metabolite	Reference Standards HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (Standard) is the analytical standard of Atazanavir. This product is intended for research and analytical applications. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

Cat. No.	Product Name	Chemical Structure

HY-17367S5

Atazanavir-d24
Atazanavir-d₂₄ (BMS-232632-d₂₄) is deuterium labeled Atazanavir. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

Atazanavir-d24

Atazanavir-d₂₄ (BMS-232632-d₂₄) is deuterium labeled Atazanavir. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp). Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks